Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

2.

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.

Lemery SJ, Zhang J, Rothmann MD, Yang J, Earp J, Zhao H, McDougal A, Pilaro A, Chiang R, Gootenberg JE, Keegan P, Pazdur R.

Clin Cancer Res. 2010 Sep 1;16(17):4331-8. doi: 10.1158/1078-0432.CCR-10-0570. Epub 2010 Jul 2.

3.

Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Reagan JL, Castillo JJ.

Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223. Review.

PMID:
21342032
4.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A; Hx-CD20-406 Study Investigators..

J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1. Erratum in: J Clin Oncol. 2010 Aug 1;28(22):3670.

5.

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

Barth MJ, Czuczman MS.

Future Oncol. 2013 Dec;9(12):1829-39. doi: 10.2217/fon.13.219.

PMID:
24295413
6.

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

Nightingale G.

Ann Pharmacother. 2011 Oct;45(10):1248-55. doi: 10.1345/aph.1P780. Epub 2011 Sep 6. Review.

PMID:
21896924
7.

Ofatumumab in the treatment of chronic lymphocytic leukemia.

Tsimberidou AM.

Drugs Today (Barc). 2010 Jul;46(7):451-61. doi: 10.1358/dot.2010.46.7.1497416. Review.

PMID:
20683500
8.

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.

O'Brien S, Osterborg A.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069. Review.

PMID:
21030349
9.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
10.

Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.

Gupta IV, Jewell RC.

Ann N Y Acad Sci. 2012 Aug;1263:43-56. doi: 10.1111/j.1749-6632.2012.06661.x. Epub 2012 Jul 25. Review.

PMID:
22830942
11.

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.

Hoyle M, Crathorne L, Garside R, Hyde C.

Health Technol Assess. 2011 May;15 Suppl 1:61-7. doi: 10.3310/hta15suppl1/07. Review.

13.

Ofatumumab for the treatment of chronic lymphocytic leukemia.

Grosicki S.

Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16. Review.

PMID:
25882470
14.

Ofatumumab: chronic lymphocytic leukaemia: a last resort.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):201-3.

PMID:
21180369
15.

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.

Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ.

Br J Haematol. 2015 Jul;170(1):40-9. doi: 10.1111/bjh.13380. Epub 2015 Mar 30.

PMID:
25825041
16.

Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Baig NA, Taylor RP, Lindorfer MA, Church AK, LaPlant BR, Pettinger AM, Shanafelt TD, Nowakowski GS, Zent CS.

J Immunol. 2014 Feb 15;192(4):1620-9. doi: 10.4049/jimmunol.1302954. Epub 2014 Jan 15.

17.

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F.

Oncologist. 2014 Jul;19(7):766-73. doi: 10.1634/theoncologist.2013-0348. Epub 2014 Jun 13. Review.

18.

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A; Hx-CD20-406 Study Investigators..

Blood. 2011 Nov 10;118(19):5126-9. doi: 10.1182/blood-2011-04-348656. Epub 2011 Aug 19.

19.

Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.

Molica S, Montillo M, Ribatti D, Mirabelli R, Tedeschi A, Ricci F, Veronese S, Vacca A, Morra E.

Haematologica. 2007 Oct;92(10):1367-74.

20.

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA.

Leuk Lymphoma. 2009 Oct;50(10):1589-96.

PMID:
19863336

Supplemental Content

Support Center